Browsing Bergen Open Research Archive by Author "Søiland, Håvard"
Now showing items 1-13 of 13
-
The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells
Helland, Thomas; Gjerde, Jennifer; Dankel, Simon N; Fenne, Ingvild Sveinsgjerd; Skartveit, Linn; Drangevåg, Andreas; Bozickovic, Olivera; Flågeng, Marianne Hauglid; Søiland, Håvard; Mellgren, Gunnar; Lien, Ernst Asbjørn (Peer reviewed; Journal article, 2015-04-13)Introduction: Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive breast cancer. Effects and side effects of tamoxifen is the sumof tamoxifen and all itsmetabolites. 4-Hydroxytamoxifen ... -
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
DeCensi, Andrea; Johansson, Harriet; Helland, Thomas; Puntoni, Matteo; Macis, Debora; Aristarco, Valentina; Caviglia, Silvia; Webber, Tania Buttiron; Briata, Irene Maria; D’Amico, Mauro; Serrano, Davide; Guerrieri-Gonzaga, Aliana; Bifulco, Ersilia; Hustad, Simon Steinar; Søiland, Håvard; Boni, Luca; Bonanni, Bernardo; Mellgren, Gunnar (Journal article; Peer reviewed, 2021)Low-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 nM) and ... -
Ekspressiv skriving som egenterapeutisk verktøy ett år etter brystkreftdiagnosen - resultater fra en beskrivende pilotstudie
Gripsrud, Birgitta Haga; Søiland, Håvard; Lode, Kirsten (Peer reviewed; Journal article, 2014)The article presents findings from a pilot study on expressive writing, a therapeutic method undescribed in a Norwegian scientific context. Objective: 1. Gain qualitative data on breast cancer women’s experiences with ... -
Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
Helland, Thomas; Alsomairy, Sarah; Lin, Chenchia; Søiland, Håvard; Mellgren, Gunnar; Hertz, Daniel Louis (Journal article; Peer reviewed, 2021)Tamoxifen is an endocrine treatment for hormone receptor positive breast cancer. The effectiveness of tamoxifen may be compromised in patients with metabolic resistance, who have insufficient metabolic generation of the ... -
Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review
Eliassen, Finn; Blåfjelldal, Vibeke; Helland, Thomas; Hjorth, Cathrine Fonnesbech; Hølland, Kari; Lode, Lise; Bertelsen, Bjørn-Erik; Janssen, Emiel; Mellgren, Gunnar; Kvaløy, Jan Terje; Søiland, Håvard; Lende, Tone Hoel (Journal article; Peer reviewed, 2023)Purpose Adjuvant endocrine treatment is essential for treating luminal subtypes of breast cancer, which constitute 75% of all breast malignancies. However, the detrimental side effects of treatment make it difficult for ... -
Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients - a randomized trial
Lende, Tone Hoel; Austdal, Marie; Varhaugvik, Anne Elin; Skaland, Ivar; Gudlaugsson, Einar; Kvaløy, Jan Terje; Akslen, Lars A.; Søiland, Håvard; Janssen, Emiel; Baak, Jan P.A. (Peer reviewed; Journal article, 2019-11-08)Background: Conflicting results have been reported on the influence of carbohydrates in breast cancer. Objective: To determine the influence of pre-operative per-oral carbohydrate load on proliferation in breast tumors. ... -
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
Helland, Thomas; Naume, Bjørn; Hustad, Steinar; Bifulco, Ersilia; Kvaløy, Jan Terje; Sætersdal, Anna Barbro; Synnestvedt, Marit; Lende, Tone Hoel; Gilje, Bjørnar; Mjaaland, Ingvil; Weyde, Kjetil; Blix, Egil Støre; Wiedswang, Gro; Borgen, Elin; Hertz, Daniel Louis; Janssen, Emiel; Mellgren, Gunnar; Søiland, Håvard (Journal article; Peer reviewed, 2021)Low steady‐state levels of active tamoxifen metabolites have been associated with inferior treatment outcomes. In this retrospective analysis of 406 estrogen receptor‐positive breast cancer (BC) patients receiving adjuvant ... -
Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study
Lende, Tone Hoel; Austdal, Marie; Bathen, Tone Frost; Varhaugvik, Anne Elin; Skaland, Ivar; Gudlaugsson, Einar; Egeland, Nina Gran; Lunde, Siri; Akslen, Lars A.; Jonsdottir, Kristin; Janssen, Emiel; Søiland, Håvard; Baak, Jan P.A. (Peer reviewed; Journal article, 2019-12-04)Background: The metabolic consequences of preoperative carbohydrate load in breast cancer patients are not known. The present explorative study investigated the systemic and tumor metabolic changes after preoperative ... -
Our genes, our selves: hereditary breast cancer and biological citizenship in Norway
Solbrække, Kari Nyheim; Søiland, Håvard; Lode, Kirsten; Gripsrud, Birgitta Haga (Peer reviewed; Journal article, 2017-03)In this paper we explore the rise of ‘the breast cancer gene’ as a field of medical, cultural and personal knowledge. We address its significance in the Norwegian public health care system in relation to so-called biological ... -
Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer
Dragvoll, Ida; Bofin, Anna M.; Søiland, Håvard; Taraldsen, Gunnar; Engstrøm, Monica J (Journal article; Peer reviewed, 2022-12-02)Background: Antihormonal treatment for hormone receptor (HR) positive breast cancer has highly beneficial effects on both recurrence rates and survival. We investigate adherence and persistence in this group of ... -
The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients
Egeland, Nina; Lunde, Siri; Jonsdottir, Kristin; Lende, Tone Hoel; Cronin-Fenton, Deirdre P.; Gilje, Bjørnar; Janssen, Emilius Adrianus Maria; Søiland, Håvard (Peer reviewed; Journal article, 2015-10-14)Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen ... -
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
Helland, Thomas; Henne, Nina; Bifulco, Ersilia; Naume, Bjørn; Borgen, Elin; Kristensen, Vessela N.; Kvaløy, Jan Terje; Lash, Timothy L; Grenaker, Grethe Irene; van Schaik, RHN; Janssen, Emiel; Hustad, Simon Steinar; Lien, Ernst Asbjørn; Mellgren, Gunnar; Søiland, Håvard (Peer reviewed; Journal article, 2017-11-28)Background: Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct measurement ... -
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
Bertelsen, Bjørn-Erik; Viste, Kristin; Helland, Thomas; Hagland, Magnus; Søiland, Håvard; Geisler, Jürgen; Lende, Tone Hoel; Lønning, Per Eystein; Sagen, Jørn Vegard; Mellgren, Gunnar; Almås, Bjørg (Journal article; Peer reviewed, 2021)Context Currently there are no assays that can simultaneously quantify serum levels of the third-generation aromatase inhibitors (AIs): letrozole, anastrozole, and exemestane, and the ultra-low levels of estrogens in ...